Targeted opening of the blood-brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma.

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2024-07-27 eCollection Date: 2024-01-01 DOI:10.1080/2162402X.2024.2385124

Jonathan G Pol, Manuela Lizarralde-Guerrero, Andrea Checcoli, Guido Kroemer

引用次数: 0

Abstract

Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood-brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.

查看原文本刊更多论文

有针对性地打开血脑屏障有助于对胶质母细胞瘤进行基于多柔比星/抗-PD-1的化疗免疫治疗。

多柔比星是一种典型的免疫原性细胞死亡（ICD）诱导剂，可通过PD-1阻断对随后的免疫疗法敏感。然而，这种全身性联合用药治疗隐藏在血脑屏障（BBB）后的胶质母细胞瘤却失效了。最近的一项研究界定了一种生物物理方法，它能使 BBB 通透，从而产生有效的临床前化学免疫疗法效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.